A detailed history of Virtus ETF Advisers LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,178 shares of JANX stock, worth $106,199. This represents 0.05% of its overall portfolio holdings.

Number of Shares
2,178
Previous 2,137 1.92%
Holding current value
$106,199
Previous $89,000 10.11%
% of portfolio
0.05%
Previous 0.05%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $1,446 - $2,060
41 Added 1.92%
2,178 $98,000
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $75,051 - $138,434
2,137 New
2,137 $89,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.03B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.